Os

27%9

28%i

55%j

19%k

UCBT, umbilical cord blood transplantation; ICBTR, International Cord Blood Transplant Registry; TNC, total nucleated cells; GVHD, graft-versus-host disease; TRM, transplant-related mortality; EFS, event-free survival; OS, overall survival; NA, not available.

aObserved at 60 days.

bObserved at 30 days.

cObserved at 50 days.

dObserved at 100 days.

eObserved in 4 of 54 patients with malignancies.

fObserved in 7 of 25 patients with malignancies that engrafted and survived 100 days.

gObserved at 1 year.

hObserved at 40 months.

iObserved at 22 months.

'Observed at 8 months.

kObserved at 3 years.

UCBT, umbilical cord blood transplantation; ICBTR, International Cord Blood Transplant Registry; TNC, total nucleated cells; GVHD, graft-versus-host disease; TRM, transplant-related mortality; EFS, event-free survival; OS, overall survival; NA, not available.

aObserved at 60 days.

bObserved at 30 days.

cObserved at 50 days.

dObserved at 100 days.

eObserved in 4 of 54 patients with malignancies.

fObserved in 7 of 25 patients with malignancies that engrafted and survived 100 days.

gObserved at 1 year.

hObserved at 40 months.

iObserved at 22 months.

'Observed at 8 months.

kObserved at 3 years.

and the mean number of CD34+ cells infused was 2.51 X 105/kg. The median time to neutrophil recovery was 24 days. Twenty-five percent of patients developed acute grade II-IV GVHD. Two patients developed chronic GVHD. The EFS at a median of 905 days was 85%.

0 0

Post a comment